Non-invasive TransplantCheck

 

On 1.9.2016, the company genEplanet in collaboration with the Medical University of Graz started a European project in the field of allograft rejection. The 34-months long project is called the “Non-invasive TransplantCheck” and its objective is to use blood samples (plasma) from heart transplant patients and monitor fluctuations of cell-free DNA, released from the donated organ into the bloodstream of the recipient. Our goal is to recognize small differences in the concentration of the cell-free DNA and link the results to the biopsy reports. Our aim is to prove that by using such minimally invasive procedure (regular venous blood draw) we will be able to monitor a potential allograft rejection and detect the rejection even before clinical indications can be seen. The project could significantly contribute to the field of transplantation and is as such conducted within the Eurostars program, co-financed by the Slovenian Ministry of economic development and technology. 

 

Eurostars

 

 

CCtest - Non-invasive blood test for early detection of colorectal cancer and its precursors

 

Since September 2016, the company genEplanet has been conducting a multicentric prospective observational study, whose goal is to validate a specific panel of metabolic markers that we managed to establish in earlier stages of development. The project’s main objective is to prove that with the chosen metabolic panel we can with high statistical probability distinguish between healthy persons and persons with colorectal cancer, as well as identify persons with adenomatous polyps.

 

The project is co-financed by Republic of Slovenia and European Union from the European Regional Development Fund: www.eu-skladi.si.

EU regionalni skladMGRT

 

 

genEplanet optimisation

 

GenePlanet is a young, fast-growing company. Due to the significant increase in the workload and the number of employees in recent years, there is a need for reorganization and optimization of working processes. Organizational strategy/objectives? *Project actions will improve the communication between customers and partners. Shorter response time will therefore increase our partner satisfaction. The optimization of production processes will contribute to higher quality services. Furthermore, undergoing the personnel reorganization will result in higher employee satisfaction and performance as well as cost time efficient management of existing assignments. Introduced improvements will enable our company to continue with the current panel of services and state-of-the-art services and processes.

The project is co-financed by Republic of Slovenia and European Union from the European Regional Development Fund: www.eu-skladi.si.

 EU regionalni sklad

 

 

genEplanet - participation in an international business event

 

GenEplanet is an innovative bio-tech company that specializes in human genetic tests and analyses. The company focuses on B2B sales channels on international markets where it creates majority of its revenue. The goal of the project was to improve market awareness of the company and its products on the key market. By attending 5th Annual Life Insurance Forum in Amsterdam GenePlanet did not only gain new sales leads but also created new business cooperation and improved sales from existing partnerships. Benefits of the participation in an international business event will also be seen in the future in form of easier approach to new markets and business opportunities.

The project is co-financed by Republic of Slovenia and European Union from the European Regional Development Fund: www.eu-skladi.si.

 EU regionalni sklad